- Home
- EMF vs BWAY Comparison
EMF vs BWAY Comparison
Compare EMF & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- BWAY
- Stock Information
- Founded
- EMF 1987
- BWAY 2003
- Country
- EMF United States
- BWAY Israel
- Employees
- EMF N/A
- BWAY N/A
- Industry
- EMF Finance/Investors Services
- BWAY Medical/Dental Instruments
- Sector
- EMF Finance
- BWAY Health Care
- Exchange
- EMF Nasdaq
- BWAY Nasdaq
- Market Cap
- EMF 192.8M
- BWAY 177.4M
- IPO Year
- EMF N/A
- BWAY 2019
- Fundamental
- Price
- EMF $12.33
- BWAY $10.72
- Analyst Decision
- EMF
- BWAY Strong Buy
- Analyst Count
- EMF 0
- BWAY 3
- Target Price
- EMF N/A
- BWAY $13.17
- AVG Volume (30 Days)
- EMF 29.3K
- BWAY 52.9K
- Earning Date
- EMF 01-01-0001
- BWAY 03-05-2025
- Dividend Yield
- EMF 6.16%
- BWAY N/A
- EPS Growth
- EMF N/A
- BWAY N/A
- EPS
- EMF N/A
- BWAY 0.04
- Revenue
- EMF N/A
- BWAY $38,631,000.00
- Revenue This Year
- EMF N/A
- BWAY $388.82
- Revenue Next Year
- EMF N/A
- BWAY $18.70
- P/E Ratio
- EMF N/A
- BWAY $138.73
- Revenue Growth
- EMF N/A
- BWAY 34.19
- 52 Week Low
- EMF $10.58
- BWAY $4.61
- 52 Week High
- EMF $12.67
- BWAY $11.25
- Technical
- Relative Strength Index (RSI)
- EMF 55.41
- BWAY 68.84
- Support Level
- EMF $12.02
- BWAY $10.08
- Resistance Level
- EMF $12.29
- BWAY $11.25
- Average True Range (ATR)
- EMF 0.11
- BWAY 0.37
- MACD
- EMF 0.06
- BWAY 0.17
- Stochastic Oscillator
- EMF 98.28
- BWAY 86.96
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.